MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Madrigal Pharmaceuticals Total Non Current Liabilities 2011-2026 | MDGL
Annual Total Non Current Liabilities Madrigal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 347 M | 119 M | 117 M | 49.3 M | 387 K | 468 K | 361 K | - | - | - | - | 4.65 M | 13.9 M | 4.46 M | 12.4 M | 13.9 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 347 M | 361 K | 56.8 M |
Quarterly Total Non Current Liabilities Madrigal Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 346 M | 345 M | 123 M | 119 M | 119 M | 118 M | 118 M | 117 M | 117 M | 116 M | 99.2 M | 84 M | 49.3 M | 49.1 M | - | 283 K | 387 K | 491 K | 594 K | 387 K | 468 K | 468 K | 468 K | 468 K | 361 K | 361 K | 361 K | 361 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 11 K | 32 K | 2.33 M | 4.65 M | 4.65 M | 4.65 M | 4.65 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 4.46 M | 4.46 M | 4.46 M | 4.46 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 346 M | 11 K | 45 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
158 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
15.9 M | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
3.48 M | - | -13.47 % | $ 169 M | France |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.17 | -2.48 % | $ 203 M |  Israel |
 |
AstraZeneca PLC
AZN
|
34.7 B | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
622 M | $ 88.82 | -0.86 % | $ 21.5 B | Germany |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.52 | -3.81 % | $ 178 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
7.32 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
128 M | - | - | $ 4.9 B | Britain |
 |
CRISPR Therapeutics AG
CRSP
|
70.2 M | $ 53.21 | -6.57 % | $ 4.78 B |  Schweiz |
 |
Galera Therapeutics
GRTX
|
64 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
645 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
13.4 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
4.97 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 29.81 | -0.42 % | $ 1.98 B | USA |
 |
Generation Bio Co.
GBIO
|
132 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
8.95 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
497 K | - | - | $ 7.46 M | Israel |
|
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.75 | -4.78 % | $ 34.3 M | Israel |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
4.56 M | $ 28.73 | -0.59 % | $ 773 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.06 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
51.9 M | - | - | $ 3.37 B | China |
|
Forte Biosciences
FBRX
|
10.5 M | $ 16.17 | -3.15 % | $ 209 M | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 14.74 | -0.37 % | $ 211 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.16 | 0.01 % | $ 5.2 M | Israel |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |